{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:08:37Z","timestamp":1790071717155,"version":"4.0.1"},"reference-count":156,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Prolactinomas account for approximately 30% to 50% of pituitary adenomas. Dopamine agonists (DAs) are the first-line treatment and effectively induce tumor regression while normalizing prolactin levels. However, DA therapy not only inhibits tumor growth but also is associated with fibrosis within the tumor. This fibrotic transformation remodels the tumor microenvironment (TME), altering cellular interactions, vascular structures, and extracellular matrix (ECM) composition. We hypothesize that this fibrotic response may not be a mere side effect; emerging, though largely indirect, evidence suggests it could potentially protect residual tumor cells by impeding drug penetration and facilitating immune evasion. Despite extensive clinical use of DAs, the mechanisms underlying DA-associated fibrosis and its implications for tumor behavior as well as patient outcomes remain poorly understood. This review integrates current knowledge regarding the pathophysiological processes leading to DA-associated fibrosis in prolactinomas, explores alterations in the TME, and assesses the clinical implications of these alterations. By integrating recent experimental and clinical studies, we aim to provide a comprehensive overview that elucidates the challenges posed by this fibrotic change in DA therapy and to propose actionable avenues for future research aimed at overcoming these obstacles.<\/jats:p>","DOI":"10.3389\/fendo.2026.1943425","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:54:42Z","timestamp":1790070882000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Dopamine agonist-associated fibrosis in prolactinomas: clinical challenges, impacts on the tumor microenvironment, and future directions"],"prefix":"10.3389","volume":"17","author":[{"given":"Chunxiao","family":"Qi","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, the First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine, the Fourth People\u2019s Hospital of Shenyang","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyuan","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, the First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Wafangdian Central Hospital","place":["Wafangdian, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, the First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanyu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, the First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, the First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, the First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaowu","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, the First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lpm.2021.104080","article-title":"Prolactinomas","volume":"50","author":"Wildemberg","year":"2021","journal-title":"Presse Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(25)00227-x","article-title":"Prolactin-secreting adenomas: pathogenesis, diagnosis, and management","volume":"13","author":"Fleseriu","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19632","article-title":"Atypical giant suprasellar prolactinoma presenting with visual field changes in the absence of symptoms of hyperprolactinemia","volume":"13","author":"Sun","year":"2021","journal-title":"Cureus"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.31348\/2023\/20","article-title":"Giant prolactinoma. a case report","volume":"79","author":"\u0160ulav\u00edkov\u00e1","year":"2023","journal-title":"Cesk Slov Oftalmol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/11795476231186062","article-title":"De novo psychiatric disorders in a woman with giant prolactinoma treated with cabergoline","volume":"16","author":"Belhadj Slimane","year":"2023","journal-title":"Clin Med Insights Case Rep"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad174","article-title":"Approach to the patient with prolactinoma","volume":"108","author":"Auriemma","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-023-00886-5","article-title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a pituitary society international consensus statement","volume":"19","author":"Petersenn","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15660","article-title":"Dopamine agonists for the treatment of pituitary tumours: from ergot extracts to next generation therapies","volume":"89","author":"Wexler","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/ncpendmet0160","article-title":"Drug insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women","volume":"2","author":"Colao","year":"2006","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s11011-018-0217-3","article-title":"Cabergoline versus bromocriptine for the treatment of giant prolactinomas: a quantitative and systematic review","volume":"33","author":"Huang","year":"2018","journal-title":"Metab Brain Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1055\/a-1525-2131","article-title":"Treatment strategies for dopamine agonist-resistant and aggressive prolactinomas: a comprehensive analysis of the literature","volume":"53","author":"Sari","year":"2021","journal-title":"Horm Metab Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqae144","article-title":"B2R-D2R interaction in prolactinomas and nonfunctional adenomas: impact on dopamine resistance","volume":"165","author":"Abeledo-MaChado","year":"2024","journal-title":"Endocrinology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1786740","article-title":"The effect of preoperative cabergoline on prolactinoma fibrosis: a case series","volume":"85","author":"Pecorari","year":"2024","journal-title":"J Neurol Surg Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad758","article-title":"Presurgical medical treatment in prolactinomas: surgical implications and pathological characteristics from 290 cases","volume":"109","author":"Chen","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(82)92756-8","article-title":"Bromocriptine: does it jeopardise the result of later surgery for prolactinomas","volume":"2","author":"Landolt","year":"1982","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s00701-024-06198-5","article-title":"Preoperative treatment with dopamine agonist therapy influences surgical outcome in prolactinoma: a retrospective single-center on 159 patients","volume":"166","author":"Ryba","year":"2024","journal-title":"Acta Neurochir (Wien)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-58-6-1179","article-title":"Perivascular fibrosis in prolactinomas: is it increased by bromocriptine","volume":"58","author":"Landolt","year":"1984","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvae055","article-title":"Cabergoline targets multiple pathways to inhibit PRL secretion and increases stromal fibrosis","volume":"190","author":"Zhang","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s11102-010-0261-4","article-title":"Effect of dopaminergic drug treatment on surgical findings in prolactinomas","volume":"14","author":"Menucci","year":"2011","journal-title":"Pituitary"},{"key":"B20","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41419-019-1526-0","article-title":"Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK\/EGR1 and AKT\/mTOR pathway respectively","volume":"10","author":"Tang","year":"2019","journal-title":"Cell Death Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114504","article-title":"Cancer-associated fibroblasts: origin, function, imaging, and therapeutic targeting","volume":"189","author":"Rimal","year":"2022","journal-title":"Adv Drug Delivery Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-023-01301-y","article-title":"Exploring the role of the tumor microenvironment in refractory pituitary tumor pathogenesis","volume":"26","author":"Ben-Shlomo","year":"2023","journal-title":"Pituitary"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1159\/000539345","article-title":"The role of programmed cell death ligand 1 expression in pituitary tumours: lessons from the current literature","volume":"114","author":"Lopes-Pinto","year":"2024","journal-title":"Neuroendocrinology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158112","article-title":"Chemokine CXCL10 modulates the tumor microenvironment of fibrosis-associated hepatocellular carcinoma","volume":"23","author":"Brandt","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113783","article-title":"Nanoparticle-mediated dual targeting of stromal and immune components to overcome fibrotic and immunosuppressive barriers in hepatocellular carcinoma","volume":"383","author":"Yin","year":"2025","journal-title":"J Control Release"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.04.021","article-title":"Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer","volume":"54","author":"Buechler","year":"2021","journal-title":"Immunity"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1088\/1758-5090\/ae6f84","article-title":"Targeting the YAP-mediated stromal signaling unlocks chemoresistance in a human organoid fibrosis model","volume":"18","author":"Xiong","year":"2026","journal-title":"Biofabrication"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147575","article-title":"TGF-\u03b2 signaling: from tissue fibrosis to tumor microenvironment","volume":"22","author":"Chung","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1530\/eo-21-0038","article-title":"Dopamine agonist therapy for prolactinomas: do we need to rethink the place of surgery in prolactinoma management","volume":"2","author":"De Sousa","year":"2022","journal-title":"Endocr Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41574-024-00978-w","article-title":"Reply to 'Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern'","volume":"20","author":"Petersenn","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41574-024-00976-y","article-title":"Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern","volume":"20","author":"De Sousa","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf025","article-title":"Circulating miR-20a-5p as a biomarker associated with cabergoline responsiveness in patients with hyperprolactinemia and pituitary adenomas","volume":"192","author":"Lee","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter","year":"2019","journal-title":"Neuroendocrinology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.6.6657","article-title":"Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101056","article-title":"Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs","volume":"73","author":"Cheng","year":"2024","journal-title":"Drug Resist Update"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1159\/000517356","article-title":"MicroRNAs in dopamine agonist-resistant prolactinoma","volume":"112","author":"Wan","year":"2022","journal-title":"Neuroendocrinology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12902-022-01009-3","article-title":"The side effects of dopamine receptor agonist drugs in Chinese prolactinoma patients: a cross sectional study","volume":"22","author":"Ke","year":"2022","journal-title":"BMC Endocr Disord"},{"key":"B39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11102-025-01517-0","article-title":"Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre","volume":"28","author":"Hamblin","year":"2025","journal-title":"Pituitary"},{"key":"B40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12902-020-0543-4","article-title":"Predictors of dopamine agonist resistance in prolactinoma patients","volume":"20","author":"Vermeulen","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"B41","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1186\/s12935-024-03529-5","article-title":"MicroRNA networks in prolactinoma tumorigenesis: a scoping review","volume":"24","author":"Rad","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1227\/01.neu.0000330406.73157.49","article-title":"Tumor tissue identification in the pseudocapsule of pituitary adenoma: should the pseudocapsule be removed for total resection of pituitary adenoma","volume":"64","author":"Lee","year":"2009","journal-title":"Neurosurgery"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11133920","article-title":"Extra-pseudocapsular transsphenoidal surgery for microprolactinoma in women","volume":"11","author":"Chen","year":"2022","journal-title":"J Clin Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1668516","article-title":"Tumor to cerebellar peduncle T2-weighted imaging intensity ratio fails to predict pituitary adenoma consistency","volume":"80","author":"Mastorakos","year":"2019","journal-title":"J Neurol Surg B Skull Base"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-016-0706-5","article-title":"Magnetic resonance elastography detects tumoral consistency in pituitary macroadenomas","volume":"19","author":"Hughes","year":"2016","journal-title":"Pituitary"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3171\/2021.6.jns204425","article-title":"Predicting pituitary adenoma consistency with preoperative magnetic resonance elastography","volume":"136","author":"Cohen-Cohen","year":"2022","journal-title":"J Neurosurg"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-63-2-383","article-title":"Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland","volume":"63","author":"Esiri","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1507\/endocrine1927.62.12_1336","article-title":"Histological changes and operative findings of pituitary adenomas after bromocriptine treatment","volume":"62","author":"Takahashi","year":"1986","journal-title":"Nihon Naibunpi Gakkai Zasshi"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1987.tb00809.x","article-title":"Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including pre-operative bromocriptine therapy","volume":"26","author":"Bevan","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11102-025-01628-8","article-title":"Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes","volume":"29","author":"Mamelak","year":"2026","journal-title":"Pituitary"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.5603\/EP.a2023.0045","article-title":"Evaluation of pulmonary side effects in prolactinoma patients treated with cabergoline","author":"Soyluk","year":"2023","journal-title":"Endokrynol Pol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luaf067","article-title":"Pulmonary fibrosis in a patient with a prolactinoma on dopamine agonists: coincidence or consequence","volume":"3","author":"Shah","year":"2025","journal-title":"JCEM Case Rep"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2020.12.008","article-title":"The risks of medical treatment of prolactinoma","volume":"82","author":"Castinetti","year":"2021","journal-title":"Ann Endocrinol (Paris)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.732282","article-title":"Loss of function in dopamine D3 receptor attenuates left ventricular cardiac fibroblast migration and proliferation in vitro","volume":"8","author":"Kisling","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111500","article-title":"Dopamine receptor agonists ameliorate bleomycin-induced pulmonary fibrosis by repressing fibroblast differentiation and proliferation","volume":"139","author":"Mou","year":"2021","journal-title":"BioMed Pharmacother"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252312483","article-title":"The activation of p300 enhances the sensitivity of pituitary adenomas to dopamine agonist treatment by regulating the transcription of DRD2","volume":"25","author":"Li","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1530\/joe-15-0451","article-title":"The pituitary TGF\u03b21 system as a novel target for the treatment of resistant prolactinomas","volume":"228","author":"Recouvreux","year":"2016","journal-title":"J Endocrinol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1491400","article-title":"Decoding tumor-fibrosis interplay: mechanisms, impact on progression, and innovative therapeutic strategies","volume":"15","author":"Chen","year":"2024","journal-title":"Front Pharmacol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1897-5","article-title":"TGF-\u03b2 orchestrates fibrogenic and developmental EMTs via the RAS effector RREB1","volume":"577","author":"Su","year":"2020","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.brainresbull.2019.03.013","article-title":"miR-93-5p targets Smad7 to regulate the transforming growth factor-\u03b21\/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma","volume":"149","author":"Hu","year":"2019","journal-title":"Brain Res Bull"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-0430","article-title":"Dopamine, dopamine D2 receptor short isoform, transforming growth factor (TGF)-beta1, and TGF-beta type II receptor interact to inhibit the growth of pituitary lactotropes","volume":"146","author":"Sarkar","year":"2005","journal-title":"Endocrinology"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2018.07.024","article-title":"Role of TGF-\u03b21\/Smad3-mediated fibrosis in drug resistance mechanism of prolactinoma","volume":"1698","author":"Hu","year":"2018","journal-title":"Brain Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/16.17.5353","article-title":"TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4","volume":"16","author":"Nakao","year":"1997","journal-title":"EMBO J"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00436-9","article-title":"Targeting TGF\u03b2 signal transduction for cancer therapy","volume":"6","author":"Liu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0699com","article-title":"Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation","volume":"18","author":"Grotendorst","year":"2004","journal-title":"FASEB J"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0625.2009.00999.x","article-title":"Induction of matrix metalloproteinase-1 by small interfering RNA targeting connective tissue growth factor in dermal fibroblasts from patients with systemic sclerosis","volume":"19","author":"Ishibuchi","year":"2010","journal-title":"Exp Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3390\/genes13040689","article-title":"Oncogenic role of connective tissue growth factor is associated with canonical TGF-\u03b2 cascade in colorectal cancer","volume":"13","author":"Hosseini","year":"2022","journal-title":"Genes (Basel)"},{"key":"B68","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41392-021-00641-0","article-title":"Signaling pathways in cancer-associated fibroblasts and targeted therapy for cancer","volume":"6","author":"Wu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2005.03.022","article-title":"Modulation of the TGFbeta\/Smad signaling pathway in mesangial cells by CTGF\/CCN2","volume":"307","author":"Wahab","year":"2005","journal-title":"Exp Cell Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.mce.2014.12.024","article-title":"The role of TGF-\u03b2\/Smad signaling in dopamine agonist-resistant prolactinomas","volume":"402","author":"Li","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-12-71","article-title":"The expression of TGF-\u03b21, Smad3, phospho-Smad3 and Smad7 is correlated with the development and invasion of nonfunctioning pituitary adenomas","volume":"12","author":"Zhenye","year":"2014","journal-title":"J Transl Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/ncomms1734","article-title":"Activation of canonical Wnt signalling is required for TGF-\u03b2-mediated fibrosis","volume":"3","author":"Akhmetshina","year":"2012","journal-title":"Nat Commun"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.7548","article-title":"Fluorofenidone affects hepatic stellate cell activation in hepatic fibrosis by targeting the TGF-\u03b21\/Smad and MAPK signaling pathways","volume":"18","author":"Peng","year":"2019","journal-title":"Exp Ther Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12902-020-00619-z","article-title":"Inhibiting MAPK14 showed anti-prolactinoma effect","volume":"20","author":"Ding","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"B75","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12902-021-00900-9","article-title":"The role of MAPK11\/12\/13\/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"B76","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.celrep.2014.09.020","article-title":"The tumor suppressor Smad4\/DPC4 is regulated by phosphorylations that integrate FGF, Wnt, and TGF-\u03b2 signaling","volume":"9","author":"Demagny","year":"2014","journal-title":"Cell Rep"},{"key":"B77","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13045-022-01252-0","article-title":"Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy","volume":"15","author":"Jiang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/978-1-0716-2553-8_16","article-title":"Cancer and apoptosis","volume":"2543","author":"Chaudhry","year":"2022","journal-title":"Methods Mol Biol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad148","article-title":"A disintegrin and metalloproteinase 22 activates integrin \u03b21 through its disintegrin domain to promote the progression of pituitary adenoma","volume":"26","author":"Xing","year":"2024","journal-title":"Neuro Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202519433","article-title":"Direct extracellular matrix modulation attenuates intestinal fibrosis via a fibronectin-targeted approach","volume":"13","author":"Ma","year":"2026","journal-title":"Adv Sci (Weinh)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1159\/000509219","article-title":"Beta-arrestin 2 is required for dopamine receptor type 2 inhibitory effects on AKT phosphorylation and cell proliferation in pituitary tumors","volume":"111","author":"Mangili","year":"2021","journal-title":"Neuroendocrinology"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123218","article-title":"A \u03b2-arrestin 2-biased dopamine receptor type 2 (DRD2) agonist is more efficacious than cabergoline in reducing cell proliferation in PRL-secreting but not in non-functioning pituitary tumor cells","volume":"15","author":"Di Muro","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102861","article-title":"Dangerous liaisons: circulating tumor cells (CTCs) and cancer-associated fibroblasts (CAFs)","volume":"12","author":"Hurtado","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B84","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1186\/s12967-024-05413-2","article-title":"Cancer-associated fibroblasts (CAFs) gene signatures predict outcomes in breast and prostate tumor patients","volume":"22","author":"Talia","year":"2024","journal-title":"J Transl Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1530\/erc-19-0327","article-title":"Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness","volume":"26","author":"Marques","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/endrev\/bnac024","article-title":"Biological and therapeutic implications of the tumor microenvironment in pituitary adenomas","volume":"44","author":"Ilie","year":"2023","journal-title":"Endocr Rev"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1055\/s-0043-119636","article-title":"Invasive pituitary adenoma-derived tumor-associated fibroblasts promote tumor progression both in vitro and in vivo","volume":"126","author":"Lv","year":"2018","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174442","article-title":"The extracellular matrix in pancreatic cancer: description of a complex network and promising therapeutic options","volume":"13","author":"Ferrara","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202512658","article-title":"Pulmonary-targeted nanoparticles interrupt the Malignant mechanical and biochemical signaling crosstalk for idiopathic pulmonary fibrosis therapy","volume":"13","author":"Li","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-1484","article-title":"Identification of functional heterogeneity of carcinoma-associated fibroblasts with distinct IL6-mediated therapy resistance in pancreatic cancer","volume":"12","author":"McAndrews","year":"2022","journal-title":"Cancer Discov"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2020_200924N1018","article-title":"miR-1246 shuttling from fibroblasts promotes colorectal cancer cell migration","volume":"68","author":"Si","year":"2021","journal-title":"Neoplasma"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15215301","article-title":"Role of tumor microenvironment in pituitary neuroendocrine tumors: new approaches in classification, diagnosis and therapy","volume":"15","author":"Tapoi","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-2914-7_12","article-title":"Fibroblast isolation from mammary gland tissue and syngeneic murine breast cancer models","volume":"2614","author":"Bartish","year":"2023","journal-title":"Methods Mol Biol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188443","article-title":"Unmasking carcinoma-associated fibroblasts: Key transformation player within the tumor microenvironment","volume":"1874","author":"Meng","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1515-2","article-title":"C3a-C3aR signaling promotes breast cancer lung metastasis via modulating carcinoma associated fibroblasts","volume":"39","author":"Shu","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.600980","article-title":"Rhabdomyosarcoma cells produce their own extracellular matrix with minimal involvement of cancer-associated fibroblasts: a preliminary study","volume":"10","author":"D'Agostino","year":"2020","journal-title":"Front Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2022.01.004","article-title":"Meaningful connections: interrogating the role of physical fibroblast cell-cell communication in cancer","volume":"154","author":"Gardiner","year":"2022","journal-title":"Adv Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02126-5","article-title":"Single-cell sequencing of PIT1-positive pituitary adenoma highlights the pro-tumour microenvironment mediated by IFN-\u03b3-induced tumour-associated fibroblasts remodelling","volume":"128","author":"Lyu","year":"2023","journal-title":"Br J Cancer"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-023-01267-3","article-title":"Single-cell transcriptomic analysis reveals tumor cell heterogeneity and immune microenvironment features of pituitary neuroendocrine tumors","volume":"16","author":"Yan","year":"2024","journal-title":"Genome Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000002178","article-title":"Single-cell and spatial transcriptomic analyses reveal heterogeneity characteristics and specific cell subtype regulators in growth hormone-secreting pituitary adenomas","volume":"111","author":"Zhang","year":"2025","journal-title":"Int J Surg"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00736-5","article-title":"Integrated proteogenomic characterization across major histological types of pituitary neuroendocrine tumors","volume":"32","author":"Zhang","year":"2022","journal-title":"Cell Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf196","article-title":"Transcriptomic classification of prolactinomas and somatotropinomas identifies subtypes with variable resistance to treatment","volume":"193","author":"Bioletto","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2019.34.3.314","article-title":"Transcriptome analysis identifies an attenuated local immune response in invasive nonfunctioning pituitary adenomas","volume":"34","author":"Kim","year":"2019","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1186\/s12967-024-05821-4","article-title":"Single-cell transcriptomics link gene expression signatures to clinicopathological features of gonadotroph and lactotroph PitNET","volume":"22","author":"Potthoff","year":"2024","journal-title":"J Transl Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1038\/s41467-025-60028-5","article-title":"Single-cell and spatial transcriptome analyses reveal tumor heterogeneity and immune remodeling involved in pituitary neuroendocrine tumor progression","volume":"16","author":"Su","year":"2025","journal-title":"Nat Commun"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae139","article-title":"Immune landscape of isocitrate dehydrogenase-stratified primary and recurrent human gliomas","volume":"26","author":"Gupta","year":"2024","journal-title":"Neuro Oncol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathmechdis-051122-110348","article-title":"Role of the microenvironment in glioma pathogenesis","volume":"19","author":"Jayaram","year":"2024","journal-title":"Annu Rev Pathol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1093\/brain\/aww096","article-title":"Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine","volume":"139","author":"Schankin","year":"2016","journal-title":"Brain"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.1996.271.6.R1594","article-title":"Ontogeny of blood-brain barrier function in ovine fetuses, lambs, and adults","volume":"271","author":"Stonestreet","year":"1996","journal-title":"Am J Physiol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1177\/19450265251375945","article-title":"Identifying hub genes associated with sex disparities in prolactinomas","volume":"29","author":"Zhang","year":"2025","journal-title":"Genet Test Mol Biomarkers"},{"key":"B111","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1146\/annurev-immunol-101921-045939","article-title":"TGF-\u03b2 regulation of T cells","volume":"41","author":"Chen","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/s41419-022-05086-z","article-title":"Targeting HIC1\/TGF-\u03b2 axis-shaped prostate cancer microenvironment restrains its progression","volume":"13","author":"Wu","year":"2022","journal-title":"Cell Death Dis"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3390\/cells14191518","article-title":"Diverse biological processes contribute to transforming growth factor \u03b2-mediated cancer drug resistance","volume":"14","author":"Heiserman","year":"2025","journal-title":"Cells"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.7150\/thno.53749","article-title":"Lactate-induced M2 polarization of tumor-associated macrophages promotes the invasion of pituitary adenoma by secreting CCL17","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115584","article-title":"Immune atlas of pituitary neuroendocrine tumors highlights endocrine-driven immune signature and therapeutic implication","volume":"44","author":"Guo","year":"2025","journal-title":"Cell Rep"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1530\/erc-23-0196","article-title":"Cytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas","volume":"31","author":"Sabini","year":"2024","journal-title":"Endocr Relat Cancer"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2020.10.005","article-title":"Prolactin: a hormone with diverse functions from mammary gland development to cancer metastasis","volume":"114","author":"Karayazi At\u0131c\u0131","year":"2021","journal-title":"Semin Cell Dev Biol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41392-025-02489-0","article-title":"Multidimensional tumor-blood profiling uncovers systemic lymphocyte-monocyte imbalance in pituitary neuroendocrine tumors","volume":"10","author":"Dai","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103643","article-title":"Prolactin's paradox: Friend, foe, or both in immune regulation","volume":"23","author":"Borba","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B120","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/sarh.2001.25482","article-title":"Bromocriptine in rheumatic and autoimmune diseases","volume":"31","author":"McMurray","year":"2001","journal-title":"Semin Arthritis Rheum"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-016-8891-x","article-title":"Prolactin has a pathogenic role in systemic lupus erythematosus","volume":"65","author":"Jara","year":"2017","journal-title":"Immunol Res"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02160.x","article-title":"Expression of hypoxia-inducible factors is correlated with the presence of a fibrotic focus and angiogenesis in pancreatic ductal adenocarcinomas","volume":"46","author":"Couvelard","year":"2005","journal-title":"Histopathology"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188356","article-title":"Fibrosis and cancer: A strained relationship","volume":"1873","author":"Piersma","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15495","article-title":"Tumor microenvironmental 15-PGDH depletion promotes fibrotic tumor formation and angiogenesis in pancreatic cancer","volume":"113","author":"Bu","year":"2022","journal-title":"Cancer Sci"},{"key":"B125","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11102-005-5081-6","article-title":"Angiogenesis in prolactinomas: regulation and relationship with tumour behaviour","volume":"8","author":"de la Torre","year":"2005","journal-title":"Pituitary"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-009-9091-1","article-title":"Microvessel density and area in pituitary microadenomas","volume":"20","author":"Jasek","year":"2009","journal-title":"Endocr Pathol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.matbio.2020.05.001","article-title":"Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer","author":"Yamauchi","year":"2020","journal-title":"Matrix Biol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2016.11.020","article-title":"Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas","volume":"153","author":"Li","year":"2017","journal-title":"Clin Neurol Neurosurg"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2014.2827","article-title":"Upregulated periostin promotes angiogenesis in keloids through activation of the ERK 1\/2 and focal adhesion kinase pathways, as well as the upregulated expression of VEGF and angiopoietin-1","volume":"11","author":"Zhang","year":"2015","journal-title":"Mol Med Rep"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1613855114","article-title":"Matrix stiffening promotes a tumor vasculature phenotype","volume":"114","author":"Bordeleau","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0824-2","article-title":"Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas","volume":"52","author":"Cai","year":"2016","journal-title":"Endocrine"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202502774","article-title":"Single-cell RNA sequencing identifies MMP11(+) cancer-associated fibroblasts as drivers of angiogenesis and bladder cancer progression","volume":"12","author":"Xu","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2005.tb00355.x","article-title":"Matrix metalloproteinases and angiogenesis","volume":"9","author":"Rundhaug","year":"2005","journal-title":"J Cell Mol Med"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249739","article-title":"The roles of matrix metalloproteinases and their inhibitors in human diseases","volume":"21","author":"Cabral-Pacheco","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1677\/joe.0.1650475","article-title":"Angiogenesis in pituitary adenomas - relationship to endocrine function, treatment and outcome","volume":"165","author":"Turner","year":"2000","journal-title":"J Endocrinol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/ph17030267","article-title":"Hitting the target! challenges and opportunities for TGF-\u03b2 inhibition for the treatment of cardiac fibrosis","volume":"17","author":"Vistnes","year":"2024","journal-title":"Pharm (Basel)"},{"key":"B137","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/toxsci\/kfaa024","article-title":"A potent pan-TGF\u03b2 neutralizing monoclonal antibody elicits cardiovascular toxicity in mice and cynomolgus monkeys","volume":"175","author":"Mitra","year":"2020","journal-title":"Toxicol Sci"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1257453","article-title":"Novel TGF-\u03b2 inhibitors ready for prime time in onco-immunology","volume":"6","author":"de Gramont","year":"2017","journal-title":"Oncoimmunology"},{"key":"B139","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12951-025-03129-z","article-title":"Enzymatically responsive nanocarriers targeting PD-1 and TGF-\u03b2 pathways reverse immunotherapeutic resistance and elicit robust therapeutic efficacy","volume":"23","author":"Yen","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2017010013","article-title":"Targeting anti-TGF-\u03b2 therapy to fibrotic kidneys with a dual specificity antibody approach","volume":"28","author":"McGaraughty","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201701156","article-title":"Tumor microenvironment-enabled nanotherapy","volume":"7","author":"Wang","year":"2018","journal-title":"Adv Healthc Mater"},{"key":"B142","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-021-01096-0","article-title":"Nanomaterials for cancer therapy: current progress and perspectives","volume":"14","author":"Cheng","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","article-title":"The cancer metabolic reprogramming and immune response","volume":"20","author":"Xia","year":"2021","journal-title":"Mol Cancer"},{"key":"B144","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12967-025-06070-9","article-title":"Tumor-associated-fibrosis and active collagen-CD44 axis characterize a poor-prognosis subtype of gastric cancer and contribute to tumor immunosuppression","volume":"23","author":"Yang","year":"2025","journal-title":"J Transl Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2023.102273","article-title":"Novel roles for cooperating collagen receptor families in fibrotic niches","volume":"85","author":"Zeltz","year":"2023","journal-title":"Curr Opin Cell Biol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.138311","article-title":"Design and evaluation of collagenase-loaded nanoparticles for mechanical intervention of orthotopic hepatocellular carcinoma in rat model","volume":"285","author":"Deng","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"6997","DOI":"10.2147\/ijn.s145951","article-title":"Nanoparticles for the treatment of liver fibrosis","volume":"12","author":"Poilil Surendran","year":"2017","journal-title":"Int J Nanomed"},{"key":"B148","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12951-025-03465-0","article-title":"Atherosclerosis enhances the efficacy of liposome-encapsulated bromocriptine in reducing the incidence of prolactinemia in pituitary tumors","volume":"23","author":"Zhang","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.608422","article-title":"The progress of immunotherapy in refractory pituitary adenomas and pituitary carcinomas","volume":"11","author":"Dai","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-023-04382-8","article-title":"Tumor immune microenvironment in pituitary neuroendocrine tumors (PitNETs): increased M2 macrophage infiltration and PD-L1 expression in PIT1-lineage subset","volume":"163","author":"Luo","year":"2023","journal-title":"J Neuro-Oncol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2020.03.007","article-title":"Overrepresentation of highly functional T regulatory cells in patients with nonfunctioning pituitary adenoma","volume":"81","author":"Han","year":"2020","journal-title":"Hum Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216908","article-title":"Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors","volume":"592","author":"Guo","year":"2024","journal-title":"Cancer Lett"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2022.101668","article-title":"Immune checkpoint inhibitor-related hypophysitis","volume":"36","author":"Mizukoshi","year":"2022","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.7098","article-title":"Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival","volume":"21","author":"Johnson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2661","article-title":"Immune checkpoint inhibitor-associated pituitary-adrenal dysfunction: a systematic review and meta-analysis","volume":"8","author":"Lu","year":"2019","journal-title":"Cancer Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat Rev Endocrinol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1943425\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:54:44Z","timestamp":1790070884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1943425\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":156,"alternative-id":["10.3389\/fendo.2026.1943425"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1943425","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1943425"}}